BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will be sharing new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at the 2024 American Society of Clinical Oncology (“ASCO”)... Read More

68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells 84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cells The majority of ELI-002-treated patients tested had antigen spreading where induced T cells targeted additional patient-specific tumor mutations beyond mKRAS The majority of patients who received a ELI-002 booster dose were observed to have durable... Read More

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting 2024 Phase 2 randomized trial in PDAC is underway with enrollment expected to complete in the fourth quarter of 2024 ELI-002 7P initial clinical trial data expected in the second quarter of 2024 Private placement... Read More

BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription agreement to sell pre-funded warrants to purchase up to 1,032,702 shares of its common stock at a purchase price of $5.81 per pre-funded... Read More

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced three upcoming poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting taking place from April 5-10, 2024, in San Diego, California. The... Read More

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34 th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET. A... Read More

Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid tumors refractory to TCR-T cell monotherapy Long-term protection against tumor recurrence in AMP-treated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by the treatment Preclinical... Read More

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses that correlated with reduced risk of relapse and death ELI-002 7P is a 7-peptide formulation of the therapeutic cancer vaccine designed to stimulate an immune response against the seven KRAS mutations that drive 25% of all solid... Read More

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will... Read More

The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid tumors, potentially defeating resistance mechanisms Elicio will present a Trial in Progress poster on the design of the AMPLIFY-7P trial at the ASCO Gastrointestinal Cancers Symposium taking place January 18-20, 2024 BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc.... Read More

Data showed ELI-002 administered as a monotherapy induced robust, polyfunctional and durable KRAS specific CD4+ and CD8+ T cell responses Tumor biomarker reduction was observed in 84% of patients correlating with a median relapse-free survival of 16.3 months Phase 2 trial of ELI-002 monotherapy in pancreatic ductal adenocarcinoma (“PDAC”) planned to initiate in early 2024 BOSTON, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Elicio... Read More

BOSTON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, announced today that it has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC. GKCC,... Read More

BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023 at 10:30 AM ET. A... Read More

ELI-002 2P promising median relapse-free survival of 16.3 months in AMPLIFY-201 Phase 1a study presented at AACR Special Conference: Pancreatic Cancer ELI-002 2P induced T cell responses correlated with an 86% reduction in the risk of progression or death Both CD4+ and CD8+ T Cells targeting mutant KRAS were induced T cell responses to ≥ two mKRAS antigens were observed in 90% of immune responders presented at the Society... Read More

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vaccine, as monotherapy, 87% (20/23) had direct ex vivo mKRAS-specific T cell responses, and 100% (23/23) had in vitro stimulated responses. The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death. Among the four patients... Read More

BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will present updated preliminary data from the ongoing Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, targeting mutated KRAS in patients with high relapse risk... Read More

ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRAS As of the April 25, 2023 data cut-off date, among the 22 evaluable patients, preliminary data from the trial suggest that those with greater than median T cell response had not reached median Relapse-Free Survival compared to median RFS of 3.91 months for patients with less than median T cell response... Read More

Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations This $2.6 million grant is an addition to the $2.8 million that GIRF awarded Elicio in September 2022 BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, “Elicio Therapeutics” or... Read More

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 at 9:30 a.m. ET. A... Read More

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that additional data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster presentation at the upcoming AACR Special Conference on... Read More

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance... Read More

BOSTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on August 21, 2023, the Company’s board of directors approved the grant of 72,980 inducement stock options to two new employees, as an inducement material to each employee entering into employment with Elicio in... Read More

ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCO AMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger becoming a publicly traded company on Nasdaq Anticipate releasing additional AMPLIFY-201 clinical data in second half 2023 BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of... Read More

AMP-CpG directed vaccine to lymph nodes inducing broad humoral and cellular immunity against multiple viral determinants expressed during the EBV life cycle AMP-CpG immunization generated persistent EBV-specific neutralizing antibodies and robust polyfunctional EBV-specific CD4+ and CD8+ T cells that were maintained for > 7 months AMP-CpG derived T cells able to protect against EBV-associated lymphoma in mouse model BOSTON,... Read More

Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchange Positive Phase 1 clinical data was recently presented at ASCO 2023 for the 2-peptide formulation of Elicio’s lead program, ELI-002, the first and only lymph node-targeted mutant KRAS (mKRAS) immunotherapy AMPLIFY-7P, a Phase 1/2 study of the 7-peptide formulation of ELI-002, is now enrolling patients with mKRAS-driven cancers... Read More

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearance Robust mKRAS-specific T cell responses induced in 87% of patients BOSTON, June 03, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel... Read More

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Brian Piekos. In connection with Mr. Piekos’ appointment, the Elicio Board of Directors approved a stock option grant to Mr.... Read More

Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023 First in human Phase 1 data on lead candidate ELI-002 to be presented at 2023 American Society of Clinical Oncology (ASCO) BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced... Read More

Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology Lead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern... Read More

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended June 30, 2022. On June 29, 2022, Angion announced discontinuation of JUNIPER, its Phase 2 dose-finding trial of ANG-3070 in patients... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value. Angion’s Board of Directors has approved engagement of Oppenheimer & Co., Inc. as the company’s exclusive... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced the discontinuation of JUNIPER, its Phase 2 dose-finding trial of ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis... Read More

Ended the quarter with $73M in cash and cash equivalents sufficient to fund operations well into 2023 Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today provided a corporate update and reported its financial results for the quarter ended March 31, 2022. “In the first quarter of... Read More

The FDA has accepted an IND application supporting clinical development of ANG-3070 in IPF Phase 1b trial to be initiated to gather tolerability, safety, and pharmacokinetic data in IPF patients Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced U.S. Food and Drug... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference. Angion’s President and CEO, Dr. Jay Venkatesan, will participate virtually in the H.C. Wainwright Global Investment Conference. Details are as follows: Event: H.C.... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference. Angion’s President and CEO, Dr. Jay Venkatesan, will participate in the Shareholder Equity Conference, held virtually. The presentation will be a fireside chat format... Read More

Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases Ended the year with nearly $89M in cash and cash equivalents Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today reported its financial results for... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in two upcoming investment conferences. Angion will participate in two investment conferences in March. At the Cowen 42 nd Annual Healthcare Conference, Angion’s President and CEO Dr. Jay Venkatesan will... Read More

First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases Angion will end 2021 with approximately $88.8 million in cash and cash equivalents Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries, today provided a corporate... Read More

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon... Read More

Angion to host a conference call today at 4:30 p.m. EST Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended September 30, 2021. “We continue to expect enrollment of the first patient in our exploratory global Phase 2... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases presented four posters at the American Society of Nephrology’s Kidney Week 2021 virtual meeting, which is being held from November 4 to 7, 2021. “We are excited to present these promising preclinical... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will participate in a fireside chat with Stifel Managing Director and Senior Analyst Annabel Samimy at the Stifel 2021 Virtual Healthcare Conference. Details are... Read More

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced it will be presenting four posters at the American Society of Nephrology’s Kidney Week 2021 virtual meeting to be held November 4-7, 2021. All Angion’s posters will be available on... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present virtually at the H.C. Wainwright 23 rd Annual Global Investment Conference and participate in a fireside chat with Oppenheimer Senior Biotech Analyst... Read More

-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases -- A global Phase 2 trial of ANG-3070 in patients with primary proteinuric kidney diseases will begin... Read More

ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases Pharmacokinetic data potentially supportive of once-daily dosing An international Phase 2 trial in patients with primary proteinuric kidney diseases will begin enrolling patients in the second half of this year Company to host a Virtual... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced that its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet the... Read More

Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the quarter ended March 31, 2021. “Angion has accomplished a great deal so far in 2021,” said Dr. Jay R. Venkatesan, Angion’s... Read More

Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020. “CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of patients... Read More

Angion Biomedica Corp . (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2020. “This a very exciting time for Angion,” said Dr. Jay R. Venkatesan,... Read More

Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, the lead book-running managers in Angion’s recent public sale of 5,750,000 shares of common stock, have agreed to... Read More

Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will present at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31 st Annual Healthcare Conference. Dr. Jay Venkatesan, Angion’s President... Read More